Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment. Issue 11 (26th November 2019)

• Record Type: Journal Article
• Authors: Ibe, Tatsuya; Hamamoto, Yoichiro; Takabatake, Mikage; Kamoshida, Shingo
• Is Part Of: BMJ case reports. Volume 12:Issue 11(2019)
• Publication Date: 2019-11-26
• Subjects: dermatology -- skin -- chemotherapy -- lung cancer (oncology); Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2019-231464
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign vascular tumour of the skin or mucous membrane. We encountered a patient with pyogenic granuloma who was treated with ramucirumab. The patient was a 48-year-old Japanese woman with advanced lung cancer who had been heavily pretreated using several lines of chemotherapy. Ramucirumab was administered as the fifth-line treatment with docetaxel. After 10 days, a painless rice-coloured or pink papule appeared on her finger. One month later, it increased in size to 20 mm. We examined the pathological condition by immunostaining using the resected specimen diagnosed as pyogenic granuloma. Paradoxically, this vascular tumour arose during the administration of an angiogenesis inhibitor.